Shareholder Update Call

March 5, 2024 4:30 pm EST

Latest News

/C O R R E C T I O N -- TC BioPharm/

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

Latest Financial Results

FY 2022

Fiscal Year Ended December 31, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2022

Company Overview

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.

TC BioPharm (TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

IR Contacts

Company

TC BioPharm Limited
Maxim 1
2 Parklands Way
Holytown, Motherwell ML1 4WR
United Kingdom
T: +44 (0) 141 433 7557
info@tcbiopharm.com

Investor Relations

IR@tcbiopharm.com

Transfer Agent

Computershare Investor Services PLC